Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) Sets New 52-Week High – Should You Buy?

Recordati Industria Chimica e Farmaceutica S.p.A. (OTCMKTS:RCDTF)’s share price reached a new 52-week high on Wednesday . The stock traded as high as $52.25 and last traded at $52.25, with a volume of 0 shares. The stock had previously closed at $52.25.

Analyst Ratings Changes

A number of research firms recently commented on RCDTF. Barclays raised Recordati Industria Chimica e Farmaceutica to a “strong sell” rating in a research note on Tuesday, October 22nd. Royal Bank of Canada raised shares of Recordati Industria Chimica e Farmaceutica to a “hold” rating in a research note on Monday, October 7th.

Recordati Industria Chimica e Farmaceutica Price Performance

The company has a debt-to-equity ratio of 0.73, a current ratio of 1.36 and a quick ratio of 0.95. The stock has a market capitalization of $10.78 billion, a PE ratio of 26.13 and a beta of 0.33. The company has a 50-day moving average of $52.25 and a two-hundred day moving average of $51.91.

About Recordati Industria Chimica e Farmaceutica

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis.